Consistent with this notion, our findings demonstrate that targeting the HGF/c-MET axis with the inhibitor capmatinib is a viable approach for CLL treatment, offering potential benefits to CLL patients. Here, MET is linked to B-cell chronic lymphocytic leukemia.